Eli Lilly and Company: pipeline and clinical trials
Eli Lilly is the developer behind four of the drugs Spectral Genomics tracks: retatrutide, orforglipron (Foundayo), lepodisiran, and muvalaplin. It is the lead sponsor of more than 240 active clinical trials, most often in obesity.
Key points
- Lilly sponsors 241 active trials on ClinicalTrials.gov, including 93 in Phase 3. Obesity and overweight are the most frequently listed conditions.
- Its oral GLP-1 drug orforglipron was FDA-approved as Foundayo on April 1, 2026, for chronic weight management.
- Lilly says its retatrutide data package is complete and plans an FDA submission in Q1 2027 (company-reported).
- Lilly is running two Lp(a) cardiovascular outcomes trials with different drugs: lepodisiran (injectable siRNA) and muvalaplin (oral).
- Its largest active trials include a 15,374-participant study of tirzepatide's effect on morbidity and mortality in obesity (SURMOUNT-MMO).
Tracked drug profiles
Drugs from this company that Spectral Genomics profiles in depth, with registry data and sourced analysis.
Retatrutide
Peptide (once-weekly injection) · Metabolic and cardiovascular
Phase 3 obesity program complete; Lilly plans to file with the FDA in Q1 2027
FDA-approvedOrforglipron (Foundayo)
Small molecule (oral, once daily) · Metabolic
FDA-approved for chronic weight management (April 2026); type 2 diabetes submitted in the U.S.
Not yet approvedLepodisiran
Small interfering RNA (siRNA) · Cardiovascular
Phase 3 outcomes trial (ACCLAIM-Lp(a)) underway; a single dose lowered Lp(a) by about 94% in Phase 2
Not yet approvedMuvalaplin
Small molecule (oral, once daily) · Cardiovascular
First oral Lp(a)-lowering drug in a Phase 3 outcomes trial (MOVE-Lp(a)), now recruiting
Active clinical trials
ClinicalTrials.gov lists 241 active trials with Eli Lilly and Company as lead sponsor (recruiting, not yet recruiting, active, or enrolling by invitation), retrieved Nov 19, 2026. Counts include only trials whose lead sponsor is registered as "Eli Lilly and Company".
By phase
| Phase 1 | 76 |
| Phase 1/2 | 6 |
| Phase 2 | 45 |
| Phase 2/3 | 1 |
| Phase 3 | 93 |
| Phase 4 | 11 |
| Not applicable | 9 |
Most common conditions
- Obesity (46)
- Overweight (39)
- Alzheimer Disease (15)
- Diabetes Mellitus, Type 2 (12)
- Neoplasm Metastasis (11)
- Breast Neoplasms (10)
- Carcinoma, Non-Small-Cell Lung (8)
- Breast Cancer (7)
Conditions as registered by the sponsor; one trial can list several.
Largest active Phase 3 trials
| Trial | Enrollment | Primary completion |
|---|---|---|
| NCT06292013 A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) | 17,300 | Mar 2029 |
| SURMOUNT-MMO · NCT05556512 A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | 15,374 | Oct 2027 |
| MOVE-Lp(a) · NCT07157774 Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) | 10,450 | Mar 2031 |
| NCT06383390 The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) | 10,000 | Feb 2029 |
| EMBER-4 · NCT05514054 A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer | 8,000 | Oct 2027 |
| NCT07241390 A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) | 7,140 | Aug 2031 |
| monarchE · NCT03155997 Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer | 5,637 | Mar 16, 2020 |
| NCT07165028 A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | 4,500 | Aug 2030 |
| ANCHOR-AD · NCT07142954 Epidemiology and Biomarker Study in Alzheimer's Disease | 3,400 | Jul 2033 |
| ATTAIN-1 · NCT05869903 A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities | 3,127 | Jul 25, 2025 |
Cardiometabolic strategy
Lilly's tracked drugs fall into two clusters.
Obesity and diabetes. Orforglipron is an approved oral GLP-1 drug for weight management, now submitted for type 2 diabetes. Retatrutide is an injectable triple agonist heading for an FDA submission in 2027. Together with tirzepatide, already marketed as Zepbound and Mounjaro, this gives Lilly injectable and oral options at different levels of efficacy.
Lipoprotein(a). Lepodisiran and muvalaplin target the same risk factor by different mechanisms. After pelacarsen's 2026 outcomes trial failed, these two outcomes trials, together with Amgen's olpasiran, are the main remaining tests of whether lowering Lp(a) prevents cardiovascular events.
What to watch
- The retatrutide FDA submission, planned for Q1 2027 (company-reported).
- An FDA decision on orforglipron for type 2 diabetes.
- Registry changes to the two Lp(a) outcomes trials, which are logged on each drug profile.
Lilly has also publicly called for action against illegal products sold as retatrutide, which is not approved anywhere (Q3 2026 SEC filing).
Recent milestones
- Mar 5, 2024ACCLAIM-Lp(a), the lepodisiran cardiovascular outcomes trial, begins. Registry
- Sep 2, 2025MOVE-Lp(a), the muvalaplin cardiovascular outcomes trial, begins. Registry
- Apr 1, 2026FDA approves Foundayo (orforglipron) for chronic weight management. Regulator
- Aug 5, 2026Lilly reports a U.S. submission for orforglipron in type 2 diabetes and plans to submit retatrutide in Q1 2027. Company-reported
- Oct 29, 2026Lilly reports positive topline results for retatrutide versus Ozempic 2 mg in a head-to-head Phase 3 trial. Company-reported
Sources
- SEC EDGAR: Eli Lilly and Company filings (CIK 59478).Regulator
- Eli Lilly and Company. Form 8-K: Q2 2026 results (August 5, 2026).Company-reported
- Eli Lilly and Company. Form 8-K: Q3 2026 results (October 29, 2026).Company-reported
- U.S. Food and Drug Administration. FDA approves first new molecular entity under National Priority Voucher program (April 1, 2026).Regulator
- ClinicalTrials.gov: active trials with this lead sponsorRegistry
This page is for education and research. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Company-reported information is labeled. See our disclaimer.